Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer.

Spratt DE, Scala LM, Folkert M, Voros L, Cohen GN, Happersett L, Katsoulakis E, Zelefsky MJ, Kollmeier MA, Yamada Y.

Brachytherapy. 2013 Sep-Oct;12(5):428-33. doi: 10.1016/j.brachy.2013.03.003. Epub 2013 Apr 23.

PMID:
23622710
2.

Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations.

Fuller DB, Naitoh J, Lee C, Hardy S, Jin H.

Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1588-97. doi: 10.1016/j.ijrobp.2007.11.067.

PMID:
18374232
3.

Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife.

Fukuda S, Seo Y, Shiomi H, Yamada Y, Ogata T, Morimoto M, Konishi K, Yoshioka Y, Ogawa K.

J Radiat Res. 2014 Nov;55(6):1114-21. doi: 10.1093/jrr/rru048. Epub 2014 Jun 23.

4.

Dosimetric evaluation of high-dose-rate interstitial brachytherapy boost treatments for localized prostate cancer.

Fröhlich G, Agoston P, Lövey J, Somogyi A, Fodor J, Polgár C, Major T.

Strahlenther Onkol. 2010 Jul;186(7):388-95. doi: 10.1007/s00066-010-2081-x. Epub 2010 Jun 24.

PMID:
20582396
5.

Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.

Raben A, Chen H, Grebler A, Geltzeiler J, Geltzeiler M, Keselman I, Litvin S, Sim S, Hanlon A, Yang J.

Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1631-8.

PMID:
15590195
6.

Open MR-guided high-dose-rate (HDR) prostate brachytherapy: feasibility and initial experiences open MR-guided high-dose-rate (HDR) prostate brachytherapy.

Lakosi F, Antal G, Vandulek C, Kovacs A, Toller GL, Rakasz I, Bajzik G, Hadjiev J, Bogner P, Repa I.

Pathol Oncol Res. 2011 Jun;17(2):315-24. doi: 10.1007/s12253-010-9319-x. Epub 2011 Jan 11.

PMID:
21221879
7.

Virtual HDR CyberKnife SBRT for Localized Prostatic Carcinoma: 5-Year Disease-Free Survival and Toxicity Observations.

Fuller DB, Naitoh J, Mardirossian G.

Front Oncol. 2014 Nov 24;4:321. doi: 10.3389/fonc.2014.00321. eCollection 2014.

8.

Focal high-dose-rate brachytherapy: a dosimetric comparison of hemigland vs. conventional whole-gland treatment.

Kamrava M, Chung MP, Kayode O, Wang J, Marks L, Kupelian P, Steinberg M, Park SJ, Demanes DJ.

Brachytherapy. 2013 Sep-Oct;12(5):434-41. doi: 10.1016/j.brachy.2012.09.002. Epub 2013 Feb 11.

PMID:
23406987
9.

Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.

Jabbari S, Weinberg VK, Kaprealian T, Hsu IC, Ma L, Chuang C, Descovich M, Shiao S, Shinohara K, Roach M 3rd, Gottschalk AR.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):228-34. doi: 10.1016/j.ijrobp.2010.10.026. Epub 2010 Dec 22.

PMID:
21183287
10.

Comparison of single and multiple dwell position methods in MammoSite high dose rate (HDR) brachytherapy planning.

Kim Y, Trombetta MG, Miften M.

J Appl Clin Med Phys. 2010 May 28;11(3):3235.

PMID:
20717093
11.

Comparison of intracavitary brachytherapy and stereotactic body radiotherapy dose distribution for cervical cancer.

Cengiz M, Dogan A, Ozyigit G, Erturk E, Yildiz F, Selek U, Ulger S, Colak F, Zorlu F.

Brachytherapy. 2012 Mar-Apr;11(2):125-9. doi: 10.1016/j.brachy.2011.12.001. Epub 2011 Dec 20.

PMID:
22192496
12.

A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.

Vargas C, Ghilezan M, Hollander M, Gustafson G, Korman H, Gonzalez J, Martinez A.

J Urol. 2005 Sep;174(3):882-7.

PMID:
16093980
13.

High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.

Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, Gustafson GS.

J Urol. 2004 Mar;171(3):1098-104.

PMID:
14767279
14.

Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report.

Martinez AA, Pataki I, Edmundson G, Sebastian E, Brabbins D, Gustafson G.

Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):61-9.

PMID:
11163498
15.
16.

Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.

Konishi K, Yoshioka Y, Isohashi F, Sumida I, Kawaguchi Y, Kotsuma T, Adachi K, Morimoto M, Fukuda S, Inoue T.

Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1003-7. doi: 10.1016/j.ijrobp.2008.12.051. Epub 2009 Apr 3.

PMID:
19345517
17.

Dosimetric and deformation effects of image-guided interventions during stereotactic body radiation therapy of the prostate using an endorectal balloon.

Jones BL, Gan G, Diot Q, Kavanagh B, Timmerman RD, Miften M.

Med Phys. 2012 Jun;39(6):3080-8. doi: 10.1118/1.4711813.

PMID:
22755693
18.

Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate.

Hermesse J, Biver S, Jansen N, Lenaerts E, Nickers P.

Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):269-76. doi: 10.1016/j.ijrobp.2009.05.046. Epub .

PMID:
19775833
19.
20.

A dosimetric selectivity intercomparison of HDR brachytherapy, IMRT and helical tomotherapy in prostate cancer radiotherapy.

Hermesse J, Biver S, Jansen N, Lenaerts E, De Patoul N, Vynckier S, Coucke P, Scalliet P, Nickers P.

Strahlenther Onkol. 2009 Nov;185(11):736-42. doi: 10.1007/s00066-009-2009-5. Epub 2009 Nov 10.

PMID:
19899007
Items per page

Supplemental Content

Write to the Help Desk